Influence of SIGLEC9 polymorphisms on COPD phenotypes including exacerbation frequency

Respirology

Volumn 22, Issue 4, 2017, Pages 684-690

  Ishii, Takeo ^a   Angata, Takashi ^b,c   Wan, Emily S ^d   Cho, Michael H ^d   Motegi, Takashi ^a   Gao, Congxiao ^c   Ohtsubo, Kazuaki ^e   Kitazume, Shinobu ^c   Gemma, Akihiko ^a   ParÉ, Peter D ^f   Lomas, David A ^g   Silverman, Edwin K ^d   Taniguchi, Naoyuki ^c   Kida, Kozui ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b INSTITUTE OF BIOLOGICAL CHEMISTRY   (Taiwan)

^c RIKEN   (Japan)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e KUMAMOTO UNIVERSITY   (Japan)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

chronic obstructive pulmonary disease; emphysema; genetics; in vitro assays; infection and inflammation

Indexed keywords

SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; SIGLEC 9 PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; DNA; LEUKOCYTE ANTIGEN; SIGLEC9 PROTEIN, HUMAN;

AGED; AIRWAY OBSTRUCTION; ARTICLE; BONE MARROW CELL; CAUCASIAN; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; GENETIC ASSOCIATION; GENETIC VARIATION; HAPLOTYPE; HUMAN; HUMAN CELL; JAPANESE (PEOPLE); LUNG EMPHYSEMA; MAJOR CLINICAL STUDY; MALE; SIGLEC9 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; CLINICAL TRIAL; GENETICS; GENOTYPE; INCIDENCE; JAPAN; METABOLISM; MIDDLE AGED; PHENOTYPE; RECURRENT DISEASE;

AGED; ANTIGENS, CD; DISEASE PROGRESSION; DNA; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECURRENCE; SIALIC ACID BINDING IMMUNOGLOBULIN-LIKE LECTINS;

EID: 85006001617     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12952     Document Type: Article

References (26)

1. Rabe K, Hurd S, Anzueto A, Barnes P, Buist S, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2007; 176: 532–55.
2. World Health Organization. World Health Statistics 2008. Geneva, WHO Press, 2008.
3. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–52.
4. Tanabe N, Muro S, Hirai T, Oguma T, Terada K, Marumo S, Kinose D, Ogawa E, Hoshino Y, Mishima M. Impact of exacerbations on emphysema progression in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2011; 183: 1653–9.
5. Chenna P, Mannino D. Outcomes of severe COPD exacerbations requiring hospitalization. Semin. Respir. Crit. Care Med. 2010; 31: 286–94.
6. Garcia-Aymerich J, Serra Pons I, Mannino D, Maas A, Miller D, Davis K. Lung function impairment, COPD hospitalisations and subsequent mortality. Thorax 2011; 66: 585–90.
7. Decramer M, Nici L, Nardini S, Reardon J, Rochester C, Sanguinetti C, Troosters T. Targeting the COPD exacerbation. Respir. Med. 2008; 102(Suppl. 1): S3–15.
8. Hurst J, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas D, Agusti A, Macnee W et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363: 1128–38.
9. Hobbs BD, Hersh CP. Integrative genomics of chronic obstructive pulmonary disease. Biochem. Biophys. Res. Commun. 2014; 452: 276–86.
10. Foreman M, DeMeo D, Hersh C, Carey V, Fan V, Reilly J, Shapiro S, Silverman E. Polymorphic variation in surfactant protein B is associated with COPD exacerbations. Eur. Respir. J. 2008; 32: 938–44.
11. Lin C, Siu L, Lin J, Liu C, Chian C, Lee C, Chang F. Mannose-binding lectin gene polymorphism contributes to recurrence of infective exacerbation in patients with COPD. Chest 2011; 139: 43–51.
12. Yang I, Seeney S, Wolter J, Anders E, McCormack J, Tunnicliffe A, Rabnott G, Shaw J, Dent A, Kim S et al. Mannose-binding lectin gene polymorphism predicts hospital admissions for COPD infections. Genes Immun. 2003; 4: 269–74.
13. Takabatake N, Shibata Y, Abe S, Wada T, Machiya J, Igarashi A, Tokairin Y, Ji G, Sato H, Sata M et al. A single nucleotide polymorphism in the CCL1 gene predicts acute exacerbations in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006; 174: 875–85.
14. Pillai S, Kong X, Edwards L, Cho M, Anderson W, Coxson H, Lomas D, Silverman E. Loci identified by genome-wide association studies influence different disease-related phenotypes in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2010; 182: 1498–505.
15. Sethi S, Murphy T. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 2355–65.
16. Angata T, Ishii T, Motegi T, Oka R, Taylor R, Soto P, Chang Y, Secundino I, Gao C, Ohtsubo K et al. Loss of Siglec-14 reduces the risk of chronic obstructive pulmonary disease exacerbation. Cell. Mol. Life Sci. 2013; 70: 3199–210.
17. Varki A, Angata T. Siglecs - the major subfamily of I-type lectins. Glycobiology 2006; 16: 1R–27R.
18. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat. Rev. Immunol. 2007; 7: 255–66.
19. Angata T, Varki A. Cloning, characterization, and phylogenetic analysis of siglec-9, a new member of the CD33-related group of siglecs. Evidence for co-evolution with sialic acid synthesis pathways. J. Biol. Chem. 2000; 275: 22127–35.
20. Carlin A, Uchiyama S, Chang Y, Lewis A, Nizet V, Varki A. Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response. Blood 2009; 113: 3333–6.
21. Jandus C, Boligan K, Chijioke O, Liu H, Dahlhaus M, Demoulins T, Schneider C, Wehrli M, Hunger R, Baerlocher G et al. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J. Clin. Invest. 2014; 124: 1810–20.
22. Tan WC, Bourbeau J, Hernandez P, Chapman KR, Cowie R, FitzGerald JM, Marciniuk DD, Maltais F, Buist AS, O'Donnell DE et al.; CanCOLD Collaborative Research Group. Exacerbation-like respiratory symptoms in individuals without chronic obstructive pulmonary disease: results from a population-based study. Thorax 2014; 69: 709–17.
23. Bowler RP, Kim V, Regan E, Williams AA, Santorico SA, Make BJ, Lynch DA, Hokanson JE, Washko GR, Bercz P et al.; COPDGene Investigators. Prediction of acute respiratory disease in current and former smokers with and without COPD. Chest 2014; 146: 941–50.
24. Woodruff PG, Barr RG, Bleecker E, Christenson SA, Couper D, Curtis JL, Gouskova NA, Hansel NN, Hoffman EA, Kanner RE et al.; SPIROMICS Research Group. Clinical significance of symptoms in smokers with preserved pulmonary function. N. Engl. J. Med. 2016; 374: 1811–21.
25. Muller J, Obermeier I, Wohner M, Brandl C, Mrotzek S, Angermuller S, Maity P, Reth M, Nitschke L. CD22 ligand-binding and signaling domains reciprocally regulate B-cell Ca2+ signaling. Proc. Natl. Acad. Sci. U. S. A. 2013; 110: 12402–7.
26. Laubli H, Pearce O, Schwarz F, Siddiqui S, Deng L, Stanczak M, Deng L, Verhagen A, Secrest P, Lusk C et al. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer. Proc. Natl. Acad. Sci. U. S. A. 2014; 111: 14211–6.